

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

6

Application Number	10/040,862
Filing Date	November 6, 2001
First Named Inventor	Alexander GAIGER et al.
Group Art Unit	1645
Examiner Name	To Be Assigned
Total Number of Pages in This Submission	6
Attorney Docket Number	014058-013520US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	References (13 total)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Return Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Peter K. Seperack	
	Reg. No. 47,932	
Signature		
Date	October 21, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

October 21, 2002

Typed or printed name	Amanda J. Gorthy	
Signature		
	Date	October 21, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


SF 1398078 v1

1645
119RECEIVED
OCT 25 2002

TECH CENTER 1600/290

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT
Attorney Docket No.: 014058-013520US
Client Reference No.: CID 00494C1



Assistant Commissioner for Patents
Washington, D.C. 20231

OCTOBER 21, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alexander GAIGER et al.

Application No.: 10/040,862

Filed: November 6, 2001

For: COMPOSITIONS AND METHODS
FOR THE DETECTION, DIAGNOSIS
AND THERAPY OF
HEMATOLOGICAL MALIGNANCIES

Examiner: To Be Assigned

Art Unit: 1645

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Reference nos. 2-3, 8-14, 19, and 23-25 are being submitted herewith. In accordance with 37 CFR §1.98(d), copies of reference nos. 1, 4-7, 15-18, and 20-22 can be found in Application No. 09/796,692, filed March 1, 2001 (Attorney Docket No. 014058-013512US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

RECEIVED
OCT 25 2002
TECH CENTER 1600/2900

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Peter Seperack
Reg. No. 47,932

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
PKS:ajg
SF 1398055 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OCT 24 2002
U.S. PATENT & TRADEMARK OFFICE
Substitute for form 1449B/PTOINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 3

Complete if Known	
Application Number	10/040,862
Filing Date	November 6, 2001
First Named Inventor	Alexander GAIGER et. al.
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	014058-013520US

RECEIVED
OCT 25 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	US 5,342,761		08-30-1994	MacLeod	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM- DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	2	PCT	WO 00/17222	A1	03-30-2000			<input type="checkbox"/>
	3	PCT	WO 01/38490	A2	05-31-2001			<input type="checkbox"/>

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	Blomberg, B. "Homo sapiens IGLC Gene" DATABASE EMBL 'Online!': ID HSIGLC3A Acc. no. X06876, April 2, 1988.	
	5	Callanan, M.B., et al. "The IgG Fc Receptor, FcgammaRIIB, is a Target for Deregulation by Chromosomal Translocation in Malignant Lymphoma" DATABASE EMBL 'Online!': Acc. no. AF209720, January 19, 2000.	
	6	DATABASE EMBL 'Online!' "NCI, CGAP, Tumor Gene Index," Acc. no. AI141708, September 28, 1998.	
	7	DATABASE EMBL 'Online!' "NIH Mammalian Gene Collection," Acc. no. AW405794, February 8, 2000.	
	8	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," PNAS USA August 14, 2001, pp. 9772-9777, Vol. 98, No. 17.	
	9	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AY043464, September 8, 2001.	
	10	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AY043465, September 8, 2001.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1398055 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet

2

of 3

Complete if Known	
Application Number	10/040,862
Filing Date	November 6, 2001
First Named Inventor	Alexander GAIGER et. al.
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	014058-013520US



TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AY043466, September 8, 2001.	
	12	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AF397452, August 22, 2001.	
	13	DAVIS, R.S. et al. "Identification of a family of Fc receptor homologs with preferential B cell expression," NCBI Sequence Viewer: Acc. no. AF397453, August 22, 2001.	
	14	HATZIVASSILIOU, G. et al. "IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy," <i>Immunity</i> March 2001, pp. 277-289, Vol. 14, No. 3.	
	15	Hillier, et al. "The WashU-Merck EST project" DATABASE EMBL 'Online!': Acc. no. R48079, May 24, 1995.	
	16	Hollis, et al. "Processed genes" DATABASE EMBL 'Online!': ID HSIGLAA Acc. no. K01326, June 13, 1985.	
	17	Klobeck, H.G. "Human Rearranged Immunoglobulin Lambda Light Chain mRNA" DATABASE EMBL 'Online!': Acc. no. X57804, July 15, 1991.	
	18	Klobeck, H.G. "Human Rearranged Immunoglobulin Lambda Light Chain mRNA" DATABASE EMBL 'Online!': Acc. no. X57820, July 15, 1991.	
	19	MILLER, I.J. et al. "IRTA: a new family of immunoglobulin-like receptors differentially expressed in B cells," NCBI Sequence Viewer: Acc. no. AF459633, January 13, 2002.	
	20	Pilkington, et al. "Human clone rev16/20Fab" DATABASE EMBL 'Online!': Acc. no. L38562, January 7, 1995.	
	21	Simpson, A.J.G. "RC-6-HT0409-231299-011-A02" DATABASE EMBL 'Online!': Acc. no. AW384715, February 6, 2000.	
	22	Vasicek and Leder, "Human Myeloma U266 Cell Line" DATABASE EMBL 'Online!': Acc. no. AAQ22491, July 31, 1992.	

Examiner Signature

Date Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1398055 v1



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	XU, M. et al. "Molecular cloning and characterization of SPAP1, an inhibitory receptor," <i>Biochem. & Biophys. Res. Comm.</i> 2001, pp. 768-775, Vol. 280.	
	24	XU, M.J. et al. "Molecular cloning and characterization of SPAP1, an inhibitory receptor," NCBI Sequence Viewer: Acc. no. AF319438, February 6, 2001.	
	25	XU, M.J. et al. "Molecular cloning and characterization of SPAP1, an inhibitory receptor," NCBI Sequence Viewer: Acc. no. AF319439, February 6, 2001.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1398055 v1

RECEIVED
OCT 25 2002
TECH CENTER 1600/2907